Source: Annual Congress 2009 - New bronchodilators
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Khindri, R. Sabo, S. Harris, S. Jennings, A. F. Drollman (West Sussex, United Kingdom; East Hanover, Miami, United States Of America). Cardiac safety of indacaterol – no clinical effect on qt in healthy subjects. Eur Respir J 2009; 34: Suppl. 53, 2031

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT trial Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 STIT-1: Evaluation of safety and efficacy of short-time TNI treatment in patients with COPD – First interim analysis Source: Annual Congress 2010 - Exercise in respiratory diseases and oxygen therapy Year: 2010 A UK based cost-utility analysis of indacaterol – A once-daily maintenance bronchodilator for patients with COPD Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) Source: Annual Congress 2009 - New bronchodilators Year: 2009 Cognitive function of patients with COPD after virtual admission – A randomized clinical trial Source: Annual Congress 2012 - COPD comorbidities II Year: 2012 A randomised double-blind, study to determine the efficacy & safety of a once-daily inhaled β2 adrenoreceptor agonist, PF-00610355 in asthmatic patients Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Heliox administration in patients with COPD exacerbation – Technical aspects Source: Annual Congress 2010 - Mechanical ventilation and weaning Year: 2010 Who win? Spirometry versus symptoms for predicting the longitudinal outcomes in COPD patients – 10 years observation Source: Annual Congress 2011 - Clinical parameters in airway diseases Year: 2011 Pharmacokinetics (PK) of mometasone furoate and indacaterol in Japanese and Caucasian healthy subjects after once daily inhalation of QMF149 Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 The occurrence of pneumonia in COPD patients treated with salmeterol xinafoate 50mcg/fluticasone propionate 250mcg (SFC250) – Interim report of post-marketing surveillance in Japan Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 Clinical efficacy and patients‘ satisfaction for 100 consequent COPD patients using tiotropium respimat Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009 Plasma and urinary concentrations of inhaled salmeterol in healthy and persons with asthma – Quantifying a doping limit Source: Annual Congress 2011 - Asthma management and response Year: 2011